Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Charles Schwab Investment Management Inc. lessened its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 29.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,048 shares of the company’s stock after selling 15,411 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.11% of Outlook Therapeutics worth $68,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Rhumbline Advisers boosted its position in shares of Outlook Therapeutics by 1,329.6% during the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock valued at $355,000 after acquiring an additional 174,896 shares in the last quarter. State Street Corp lifted its stake in Outlook Therapeutics by 10.0% during the third quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after purchasing an additional 21,201 shares during the period. Geode Capital Management LLC boosted its holdings in Outlook Therapeutics by 49.2% during the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after purchasing an additional 112,812 shares in the last quarter. Barclays PLC grew its stake in shares of Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Outlook Therapeutics by 44.8% in the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company’s stock worth $56,000 after buying an additional 9,211 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Stock Performance

Outlook Therapeutics stock opened at $1.22 on Wednesday. The business’s fifty day moving average is $1.63 and its two-hundred day moving average is $3.13. The firm has a market cap of $39.06 million, a P/E ratio of -0.16 and a beta of 0.54. Outlook Therapeutics, Inc. has a 52 week low of $0.87 and a 52 week high of $10.95.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04). On average, equities research analysts predict that Outlook Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Chardan Capital restated a “neutral” rating and issued a $3.00 target price on shares of Outlook Therapeutics in a research note on Tuesday, February 18th. HC Wainwright dropped their target price on shares of Outlook Therapeutics from $30.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. Finally, Ascendiant Capital Markets reduced their price target on shares of Outlook Therapeutics from $33.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, February 24th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.20.

Outlook Therapeutics Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.